# Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

> **NCT02840539** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 19 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Bortezomib, Cytarabine, Dexamethasone, Pegteograstim

## Key facts

- **NCT ID:** NCT02840539
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-11
- **Primary completion:** 2021-03-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840539, "Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02840539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*